Ken Griffin Relay Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$6.23 - $9.51 $105,910 - $161,670	17,000 Added 2833.33%	17,600 $124,000
Q2 2024 Aug 14, 2024	SELL	$5.9 - $8.02 $6,490 - $8,822	-1,100 Reduced 64.71%	600 $3,000
Q1 2024 May 15, 2024	SELL	$7.5 - $12.07 $42,000 - $67,592	-5,600 Reduced 76.71%	1,700 $14,000
Q4 2023 Feb 14, 2024	SELL	$6.01 - $11.48 $20,434 - $39,032	-3,400 Reduced 31.78%	7,300 $80,000
Q3 2023 Nov 14, 2023	SELL	$8.24 - $12.97 $88,168 - $138,779	-10,700 Reduced 50.0%	10,700 $89,000
Q2 2023 Aug 14, 2023	SELL	$9.99 - $18.27 $474,525 - $867,825	-47,500 Reduced 68.94%	21,400 $268,000
Q1 2023 May 15, 2023	BUY	$15.0 - $22.76 $1.03 Million - $1.56 Million	68,700 Added 34350.0%	68,900 $1.13 Million
Q4 2022 Feb 14, 2023	SELL	$14.16 - $24.02 $158,592 - $269,024	-11,200 Reduced 98.25%	200 $2,000
Q3 2022 Nov 14, 2022	BUY	$18.07 - $31.37 $205,998 - $357,618	11,400 New	11,400 $255,000

204

156M

207K

40K

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $571M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.